Navigation Links
Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC
Date:5/31/2011

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome (HUS) after an infection with enterohemorrhagic Escherichia coli (EHEC). The infections occurred in 2010. EHEC are the bacteria that cause the current wave of infections that have already claimed ten lives in Germany. The number of suspected and confirmed cases of EHEC has now reached 700.

Eculizumab has been approved in Germany since 2007 and is used to treat a rare blood disease and a rare congenital form of HUS. Two years ago, American physicians reported similar success in children with this form of HUS (NEJM 2009; 360:544-546).

The children suffered from kidney failure and severe neurological disorders. "After several exchanges of blood plasma had no effect, we decided to attempt treatment with Eculizumab," reports Professor Dr. Franz Schaefer, head of the section of Pediatric Nephrology at the Center for Child and Adolescent Medicine at Heidelberg University Hospital.

Within 24 hours of the initial infusion, which was repeated once or twice at intervals of seven days, the clinical condition of the children improved dramatically. Dialysis due to acute kidney failure from HUS could be discontinued. All three children recovered and had no sequelae even six months after the illness.

The researchers decided on using the monoclonal antibody Eculizumab as it interrupts the destructive immune reactions that occur after an infection with EHEC. Eculizumab binds to protein C5, which activates what is called the complement cascade and lead to the destruction of blood cells among other things. With EHEC infections there can also be complement activation, triggered by the Shiga toxin formed by the bacteria.

"We now hope that these results will help the acutely ill patients," said Professor Schaefer. He assumes that even adult patients can profit from therapy with the antibody. "Because of the epidemic in Germany, the publishers of the New England Journal of Medicine decided to accelerate the publishing date of the article, which they have had since February, and they published it immediately after reviewing it," said Schaefer. In addition, the article was sent to all kidney specialists in Germany.

Meanwhile, first treatments of adults and children in German hospitals have started. The German Society of Nephrologists has issued guidelines that the antibody may be given if all others standard treatments like dialysis and plasmapheresis have failed.


'/>"/>

Contact: Dr. Annette Tuffs
annette.tuffs@med.uni-heidelberg.de
49-622-156-4536
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. Accurate interpretation of antinuclear antibodies test key to confirming autoimmune disease
2. Why so many antibodies fail to protect against HIV infection
3. Novel autoantibodies identified in patients with necrotizing myopathy
4. Manmade antibodies hold biomedical promise
5. Antibodies linked to cardiovascular disease increase in patients with active lupus
6. Low levels of natural antibodies behind stroke
7. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
8. Cryoablation used to successfully treat atrial fibrillation at the Montreal Heart Institute
9. Successful depression treatment of mothers has long-term effects on offspring
10. Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes
11. Successful Schools May Help Keep Kids Out of Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic and ... website, which launched October 17, 2016, features comprehensive information regarding a wide range ... Visitors and patients can discover the latest clinical dermatology treatments for medical skin ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... , ... December 07, 2016 , ... “Walking With God: ... stories that will inspire the reader to be aware of God's direction in their ... published author, Sanford Smith, retired teacher and active church leader. , Sanford ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, ... International Probiotic Association’s Washington DC workshop on November 2nd. The conference was an ... regarding probiotic dietary supplement regulations. , Dr. Leyer spoke about two main ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 Eurofins Genomics today ... the College of American Pathologists (CAP) and certification ... its new laboratory in Louisville, KY ... North American headquarters. "Our new CLIA-licensed ... which is still considered the ,Gold Standard, method ...
(Date:12/6/2016)... WESTLAKE VILLAGE, Calif. , Dec. 6, ... a privately held, clinical-stage medical dermatology and ... Creabilis plc, a privately held specialty pharmaceutical ... for common inflammatory skin conditions, including psoriasis, ... terms of the agreement, Sienna will make ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
Breaking Medicine Technology: